Roberta Zanardini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1305795/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum and plasma BDNF levels in major depression: A replication study and meta-analyses. World Journal of Biological Psychiatry, 2010, 11, 763-773.	1.3	363
2	Association between â^'G308A tumor necrosis factor alpha gene polymorphism and schizophrenia. Molecular Psychiatry, 2001, 6, 79-82.	4.1	172
3	Electroconvulsive Therapy (ECT) increases serum Brain Derived Neurotrophic Factor (BDNF) in drug resistant depressed patients. European Neuropsychopharmacology, 2006, 16, 620-624.	0.3	149
4	Effect of repetitive transcranial magnetic stimulation on serum brain derived neurotrophic factor in drug resistant depressed patients. Journal of Affective Disorders, 2006, 91, 83-86.	2.0	137
5	Serum Brain-Derived Neurotrophic Factor Levels in Different Neurological Diseases. BioMed Research International, 2013, 2013, 1-7.	0.9	137
6	Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. International Journal of Neuropsychopharmacology, 2010, 13, 103.	1.0	82
7	Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia. Biological Psychiatry, 2002, 51, 480-484.	0.7	81
8	5-HTTLPR and BDNF Val66Met polymorphisms and response to rTMS treatment in drug resistant depression. Neuroscience Letters, 2008, 437, 130-134.	1.0	79
9	Serum levels of brain-derived neurotrophic factor in drug-naÃ⁻ve obsessive–compulsive patients: A case–control study. Journal of Affective Disorders, 2010, 122, 174-178.	2.0	76
10	Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011, 35, 1322-1325.	2.5	73
11	VEGF serum levels in depressed patients during SSRI antidepressant treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 146-149.	2.5	61
12	MiRNA Profiling in Plasma Neural-Derived Small Extracellular Vesicles from Patients with Alzheimer's Disease. Cells, 2020, 9, 1443.	1.8	60
13	The 196C/A (val66met) polymorphism of the BDNF gene is significantly associated with binge eating behavior in women with bulimia nervosa or binge eating disorder. Neuroscience Letters, 2006, 406, 133-137.	1.0	58
14	BDNF serum levels, but not BDNF Val66Met genotype, are correlated with personality traits in healthy subjects. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 323-329.	1.8	54
15	Association between IL-1β -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia. Journal of Psychiatric Research, 2003, 37, 457-462.	1.5	52
16	Diagnostic accuracy of markers for prodromal Alzheimer's disease in independent clinical series. Alzheimer's and Dementia, 2013, 9, 677-686.	0.4	51
17	Supporting evidence for using biomarkers in the diagnosis of MCI due to AD. Journal of Neurology, 2013, 260, 640-650.	1.8	50
18	Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer's disease. Neuroscience Letters, 2004. 356. 119-122.	1.0	49

Roberta Zanardini

#	Article	IF	CITATIONS
19	A multi-element psychosocial intervention for early psychosis (GET UP PIANO TRIAL) conducted in a catchment area of 10 million inhabitants: study protocol for a pragmatic cluster randomized controlled trial. Trials, 2012, 13, 73.	0.7	47
20	The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment. Journal of Neurology, 2010, 257, 2004-2014.	1.8	44
21	Haptoglobin polymorphism and schizophrenia: Genetic variation on chromosome 16. Psychiatry Research, 2001, 104, 1-9.	1.7	40
22	Serum brain-derived neurotrophic factor (BDNF) levels in attention deficit–hyperactivity disorder (ADHD). European Child and Adolescent Psychiatry, 2014, 23, 173-177.	2.8	40
23	MCP-1 gene (SCYA2) and schizophrenia: A case-control association study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 132B, 1-4.	1.1	39
24	Alterations of Brain-Derived Neurotrophic Factor Serum Levels in Patients with Alcohol Dependence. Alcoholism: Clinical and Experimental Research, 2011, 35, no-no.	1.4	36
25	Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. Acta Psychiatrica Scandinavica, 2014, 129, 461-466.	2.2	34
26	Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. BioTechniques, 2014, 57, 111-114.	0.8	34
27	Glucose metabolism alterations in patients with bipolar disorder. Journal of Affective Disorders, 2015, 184, 293-298.	2.0	34
28	Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. Alzheimer's and Dementia, 2012, 8, 520-527.	0.4	32
29	Immune and metabolic alterations in first episode psychosis (FEP) patients. Brain, Behavior, and Immunity, 2018, 70, 315-324.	2.0	31
30	The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort. Journal of Alzheimer's Disease, 2017, 61, 753-760.	1.2	26
31	Molecular mechanisms in cognitive frailty: potential therapeutic targets for oxygen-ozone treatment. Mechanisms of Ageing and Development, 2020, 186, 111210.	2.2	23
32	α-Thalassaemia as a result of a novel splice donor site mutation of the α1 -globin gene. British Journal of Haematology, 2000, 110, 694-698.	1.2	22
33	Plasma Extracellular Vesicle Size and Concentration Are Altered in Alzheimer's Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia. Frontiers in Cell and Developmental Biology, 2021, 9, 667369.	1.8	18
34	BDNF Val66Met polymorphism and protein levels in Amniotic Fluid. BMC Neuroscience, 2010, 11, 16.	0.8	16
35	Molecular Pathways Bridging Frontotemporal Lobar Degeneration and Psychiatric Disorders. Frontiers in Aging Neuroscience, 2016, 8, 10.	1.7	16
36	Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 61, 1477-1483.	1.2	15

Roberta Zanardini

#	Article	IF	CITATIONS
37	Childhood trauma and glucose metabolism in patients with first-episode psychosis. Psychoneuroendocrinology, 2020, 113, 104536.	1.3	15
38	Correlations between immune and metabolic serum markers and schizophrenia/bipolar disorder polygenic risk score in firstâ€episode psychosis. Microbial Biotechnology, 2020, 14, 507-511.	0.9	15
39	Serum leptin levels are higher in females affected by frontotemporal lobar degeneration than Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 79, 712-715.	0.9	12
40	Insulin-like growth factor binding protein 2 in bipolar disorder: An expression study in peripheral tissues. World Journal of Biological Psychiatry, 2018, 19, 610-618.	1.3	12
41	Serum Levels of Insulin-Like Growth Factor-1 and Obsessive-Compulsive Disorder: A Case-Control Study. Neuropsychobiology, 2016, 74, 15-21.	0.9	8
42	Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer's Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene. International Journal of Molecular Sciences, 2021, 22, 13633.	1.8	8
43	Cerebrospinal Fluid EV Concentration and Size Are Altered in Alzheimer's Disease and Dementia with Lewy Bodies. Cells, 2022, 11, 462.	1.8	7
44	Serum C-Peptide, Visfatin, Resistin, and Ghrelin are Altered in Sporadic and GRN-Associated Frontotemporal Lobar Degeneration. Journal of Alzheimer's Disease, 2018, 61, 1053-1060.	1.2	6
45	Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia. Frontiers in Neuroscience, 2022, 16, 758182.	1.4	4